文献速递角膜与眼表疾病

辅助口服伏立康唑治疗镰刀菌性角膜炎:真菌性溃疡治疗试验II的二次分析

Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

该研究为多中心双盲安慰剂对照随机临床试验的预设亚组分析,纳入240例培养阳性真菌性角膜溃疡且基线视力20/400或更差的患者,其中72例为镰刀菌阳性。镰刀菌性角膜炎患者随机接受口服伏立康唑或安慰剂,结果显示口服伏立康唑组角膜穿孔或治疗性穿透性角膜移植的风险降低(HR 0.43,95%CI 0.22-0.84,P=0.01),3周和3个月浸润/瘢痕尺寸减小,3个月视力有改善趋势但未达统计学显著(P=0.052)。作者认为镰刀菌性角膜炎可能从口服伏立康唑联合局部那他霉素中获益,医生应考虑在此类病例中处方口服伏立康唑。

要点

  • 镰刀菌性角膜炎患者口服伏立康唑较安慰剂降低穿孔或治疗性角膜移植风险(HR 0.43,95%CI 0.22-0.84,P=0.01)。
  • 口服伏立康唑组3周浸润/瘢痕尺寸减少1.89 mm(95%CI -2.69至-1.09,P<0.001),3个月减少0.83 mm(95%CI -1.33至-0.32,P=0.001)。
  • 3个月logMAR视力平均改善0.29(Snellen等效20/40),但未达统计学显著(95%CI -0.57至0.002,P=0.052)。

核心结论

  • 尽管MUTT II未发现对所有角膜溃疡的获益,镰刀菌性角膜炎可能从局部那他霉素基础上加用口服伏立康唑中获益,作者建议医生应考虑在此类病例中处方口服伏立康唑。

研究设计与样本

  • 多中心、双盲、安慰剂对照随机临床试验的预设亚组分析,纳入240例培养阳性真菌性角膜溃疡且基线视力20/400或更差的患者,来自印度Aravind眼科系统、尼泊尔Lumbini眼科医院和Bharatpur眼科医院以及加州大学旧金山分校。
  • 入组始于2010年5月24日,末例患者研究访视于2015年11月23日;所有患者接受1%局部伏立康唑,MUTT II结果公布后所有患者加用5%局部那他霉素。
  • 数据分析于2016年9月2日至10月28日进行;240例中72例(30.4%)培养阳性为镰刀菌属,其中33例(45.8%)随机至口服伏立康唑组,39例(54.2%)随机至安慰剂组。

主要发现

  • 镰刀菌性角膜炎患者中,口服伏立康唑组较安慰剂组在控制基线浸润深度后,穿孔或治疗性穿透性角膜移植的风险降低至0.43倍(95%CI 0.22-0.84,P=0.01)。
  • 口服伏立康唑组较安慰剂组3周浸润和/或瘢痕尺寸减少1.89 mm(95%CI -2.69至-1.09 mm,P<0.001),3个月减少0.83 mm(95%CI -1.33至-0.32 mm,P=0.001),均已校正基线值。
  • 口服伏立康唑组较安慰剂组3个月logMAR视力平均改善0.29(Snellen等效20/40),但未达统计学显著(95%CI -0.57至0.002,P=0.052)。

关键数值与推荐

  • 主要结局为角膜穿孔率或需治疗性穿透性角膜移植;次要结局包括3个月再上皮化率、最佳矫正视力、浸润或瘢痕尺寸。
  • 镰刀菌性角膜炎亚组中,口服伏立康唑组33例(45.8%),安慰剂组39例(54.2%);41例(56.9%)男性,31例(43.1%)女性;中位年龄50岁(四分位距45-57岁)。

临床怎么用

  • 作者建议医生应考虑在镰刀菌性角膜炎病例中处方口服伏立康唑(联合局部那他霉素)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fusarium keratitis is common and often results in poor outcomes. No new treatments since natamycin have become available. OBJECTIVE: To explore the role of adjuvant oral voriconazole on clinical outcomes in Fusarium keratitis. DESIGN, SETTING, AND PARTICIPANTS: In this prespecified subgroup analysis of a multicenter, double-masked, placebo-controlled randomized clinical trial, 240 patients from the Aravind Eye Care System in India, the Lumbini Eye Hospital and Bharatpur Eye Hospital in Nepal, and the University of California, San Francisco, who had culture-positive fungal ulcer and baseline visual acuity of 20/400 or worse were randomized to receive oral voriconazole vs placebo. Enrollment started May 24, 2010, and the last patient study visit was November 23, 2015. All patients received topical voriconazole, 1%, and after the results of the Mycotic Ulcer Treatment Trial (MUTT) II became available, topical natamycin, 5%, was added for all patients. Data analysis was performed from September 2 to October 28, 2016. MAIN OUTCOMES AND MEASURES: The primary outcome of the trial was the rate of corneal perforation or the need for therapeutic penetrating keratoplasty. Secondary outcomes included rate of reepithelialization, best spectacle-corrected visual acuity, and infiltrate or scar size at 3 months. RESULTS: Of the 240 study participants, 72 (30.4%) were culture positive for Fusarium species (41 [56.9%] male and 31 [43.1%] female; median [interquartile range] age, 50 [45-57] years). Of these, 33 (45.8%) were randomized to oral voriconazole and 39 (54.2%) to placebo. Fusarium ulcers randomized to oral voriconazole had a 0.43-fold decreased hazard of perforation or therapeutic penetrating keratoplasty compared with placebo after controlling for baseline infiltrate depth (95% CI, 0.22-fold to 0.84-fold; P = .01). Multiple linear regression revealed a 1.89-mm decreased infiltrate and/or scar size at 3 weeks (95% CI, -2.69 to -1.09 mm; P < .001) and a 0.83-mm decreased infiltrate and/or scar size at 3 months after correcting for baseline values (95% CI, -1.33 to -0.32 mm; P = .001) in eyes randomized to oral voriconazole vs placebo. Eyes treated with oral voriconazole also had a mean 0.29 decreased logMAR (improved) (Snellen equivalent 20/40) visual acuity at 3 months after controlling for baseline visual acuity, although this finding was not statistically significant (95% CI, -0.57 to 0.002; P = .052). CONCLUSIONS AND RELEVANCE: Although MUTT II could not find a benefit for all corneal ulcers, Fusarium keratitis may benefit from the addition of oral voriconazole to topical natamycin, and physicians should consider prescribing oral voriconazole in these cases. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00996736.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Prajna NV, Krishnan T, Rajaraman R, et al. Adjunctive Oral Voriconazole Treatment of Fusarium Keratitis: A Secondary Analysis From the Mycotic Ulcer Treatment Trial II. JAMA Ophthalmol. 2017. PMID: 28426856. doi:10.1001/jamaophthalmol.2017.0616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。